Works cited GLP-1 and Appetite Control: How it Works and Why it's Effective - Westlake Dermatology, accessed April 22, 2025, Role of GLP-1 Receptor Agonists for Weight Loss - YouTube, accessed April 22, 2025, Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists - PubMed Central, accessed April 22, 2025, Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks, accessed April 22, 2025, How do Ozempic, Mounjaro, Wegovy, Zepbound compare for weight loss
FDA-approved injectable GLP-1 medications include: Semaglutide (Ozempic 0.5-2 mg weekly for diabetes
470,478,482,483,484 GLP-1RAs in the digestive system Treatment with GLP-1RAs can alleviate insulin signaling by reducing the phosphorylation of Akt protein (Decreased Akt-P) and activating Protein Kinase C- (PKC-)
Rapid or significant weight loss can cause facial volume loss, hollowing of the cheeks and deeper lines, giving the face a more tired appearance
Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy
Currently, GLP-1R agonists are mainly targeted on the endogenous GLP-1R signaling system, which causes GLP-1R agonists to have many pharmacodynamic characteristics like GLP-1
